Stock data
Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Corporation (ABUS) reported revenue of US$14.08M and net income of -US$33.50M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$14.08M | — | -US$38.16M | -US$33.50M | — |
| 2024 | US$6.17M | — | -US$76.32M | -US$69.92M | — |
| 2023 | US$18.14M | — | -US$78.10M | -US$72.85M | — |
| 2022 | US$39.02M | — | -US$65.46M | -US$69.46M | — |
| 2021 | US$10.99M | — | -US$73.52M | -US$76.25M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$1.01M | -US$5.14M | — |
| 2026-03-31 | US$179.13M | US$169.69M | — |
| 2025-12-31 | US$1.05M | -US$3.76M | — |
| 2025-09-30 | US$0.53M | -US$7.74M | — |
| 2025-06-30 | US$10.74M | US$2.52M | — |
| 2025-03-31 | US$1.76M | -US$24.53M | — |
| 2024-12-31 | US$1.57M | -US$12.53M | — |
| 2024-09-30 | US$1.34M | -US$19.72M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.